Licensing · Southeast Asia · Announced 2 Sept 2026
Keymed Biosciences → Aeira
Keymed Biosciences granted Singapore-based Aeira exclusive rights to its approved IL-4Rα antibody stapokibart across 11 Southeast Asian and 5 Central Asian markets plus Hong Kong and Macao, for an upfront, milestones and high double-digit royalties.
Parties: Keymed Biosciences (China) → Aeira (Singapore)
- Deal type
- Licensing
- Value
- Undisclosed
- Territory
- 18 markets: Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand, Timor-Leste, Vietnam; Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Uzbekistan; Hong Kong and Macao
- Therapeutic area
- Immunology / Inflammation
- Assets
- stapokibart; CM310
- Announced
- 2 Sept 2026
Our analysis
Why this matters
China's Keymed Biosciences (HKEX: 2162) has granted Aeira Pte. Ltd. an exclusive licence to register and commercialise stapokibart (Kangyueda, CM310) in 18 markets: all 11 Southeast Asian countries, five Central Asian states and Hong Kong and Macao. Keymed receives an undisclosed upfront payment, per-country approval and commercial milestones, and royalties of up to a high double-digit percentage of net sales. Keymed keeps manufacturing and supply. The deal was disclosed in a voluntary announcement on 2 September 2026.
Stapokibart is the first domestically developed IL-4Rα antibody approved by China's NMPA, for adult moderate-to-severe atopic dermatitis (September 2024), chronic rhinosinusitis with nasal polyps (December 2024) and seasonal allergic rhinitis (February 2025). No approvals in the licensed territories were reported.
The full analysis is free to read with a work email on this page.